Last reviewed · How we verify
placebo mometasone
This is a placebo formulation with no active pharmacological mechanism.
This is a placebo formulation with no active pharmacological mechanism. Used for Control/comparator in clinical trials for allergic rhinitis or asthma (no therapeutic indication).
At a glance
| Generic name | placebo mometasone |
|---|---|
| Also known as | placebo |
| Sponsor | Medical University of Lodz |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Dermatology |
| Phase | FDA-approved |
Mechanism of action
Placebo mometasone is a control preparation used in clinical trials and research studies. It contains no active mometasone ingredient and produces therapeutic effects only through placebo response mechanisms. It is used as a comparator arm in studies evaluating the efficacy of active mometasone formulations.
Approved indications
- Control/comparator in clinical trials for allergic rhinitis or asthma (no therapeutic indication)
Common side effects
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia (PHASE3)
- Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort) (PHASE3)
- A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps (PHASE3)
- A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps (PHASE3)
- A Proof-of-concept Study of Lunsekimig Compared With Placebo in Adults With Chronic Rhinosinusitis With Nasal Polyps (PHASE2)
- A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma. (PHASE3)
- Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (PHASE3)
- Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- placebo mometasone CI brief — competitive landscape report
- placebo mometasone updates RSS · CI watch RSS
- Medical University of Lodz portfolio CI